Welcome to our dedicated page for Autolus Therapeutics plc American Depositary Share news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics plc American Depositary Share stock.
Autolus Therapeutics plc (NASDAQ: AUTL) is a pioneering biopharmaceutical company dedicated to the development and commercialization of engineered T-cell immunotherapy products. These innovative therapies are designed to treat life-threatening cancers with remarkable efficacy. Autolus is at the forefront of biotechnology, focusing on both haematological and solid tumors using patient-specific T-cell therapies.
At the heart of Autolus' clinical-stage pipeline is obecabtagene autoleucel (obe-cel). Additional promising candidates include AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. These products represent the next generation of programmed T-cell therapies, offering new hope for cancer patients worldwide.
Autolus' strategic initiatives are equally impressive. The company has formed a strategic alliance with BioNTech SE, a key player in the biotech industry. This partnership is poised to enhance the development and reach of Autolus' therapies. Additionally, Autolus has successfully completed an underwritten offering, strengthening its financial foundation.
Recent financial results highlight the company's strong performance. For the full year ended December 31, 2023, Autolus reported unaudited financial results, including significant UK SME R&D Tax Credits. These credits amounted to $19.5 million and $24.6 million for the years ended December 31, 2023, and 2022, respectively, providing a substantial boost to their research and development efforts.
Looking ahead, Autolus has outlined key updates and anticipated milestones for obe-cel, along with financial results for the quarter ended March 31, 2024. These updates are critical for investors and stakeholders who are keen to track the company's progress and achievements.
In summary, Autolus Therapeutics plc is leading a transformative revolution in medicine, treating life-threatening diseases through cutting-edge T-cell therapies. The company's strategic partnerships, robust pipeline, and solid financials position it as a leader in the biopharmaceutical industry.
Autolus Therapeutics has entered a strategic agreement with Bristol Myers Squibb to incorporate its proprietary RQR8 safety switch into selected cell therapy programs targeting cancer treatments. This agreement includes an upfront payment, potential option exercise fees, development milestone payments, and royalties on net sales of products utilizing the RQR8 switch. The RQR8 technology enhances safety in cell therapies, allowing for controlled elimination of cells experiencing severe side effects. This partnership aims to improve patient outcomes and represents a significant advancement in the field of advanced cell therapies.
Scholar Rock has appointed Dr. Jay Backstrom as CEO-Elect, effective
Pyramid Biosciences has appointed Dr. Nushmia Khokhar as the new Chief Medical Officer to lead the company's clinical pipeline advancements. Dr. Khokhar, previously with Umoja Biopharma and Autolus Therapeutics, brings extensive experience in oncology clinical development. The CEO, Brian Lestini, expressed confidence in her leadership during this growth phase. Dr. Khokhar's background includes significant roles at Johnson & Johnson, where she directed successful clinical trials for cancer therapies. Pyramid Biosciences focuses on creating precision therapies for serious diseases.
Autolus Therapeutics announced its Q2 2022 operational and financial results, highlighting significant advancements in its clinical pipeline. The company received RMAT designation from the FDA for obe-cel in April 2022 and continues to progress in the pivotal Phase 2 FELIX trial for r/r ALL. Financially, Autolus reported a net loss of $42.1 million and operating expenses of $46.5 million for the quarter. Cash reserves decreased to $216.4 million, extending the runway into 2024. Initial results from the FELIX trial are anticipated in Q4 2022.
Autolus Therapeutics plc (Nasdaq: AUTL) will release its second quarter 2022 financial results and operational highlights before the U.S. market opens on August 4, 2022. A conference call and webcast will be held at 8:30 am ET/1:30 pm BST to discuss these results and provide a business update. Participants must pre-register to receive dial-in information. The webcast will also be available for replay in the events section of Autolus' website.
Autolus Therapeutics plc (Nasdaq: AUTL) will announce its Q2 2022 financial results and operational highlights on August 4, 2022, prior to the U.S. market opening. A conference call and webcast featuring management will occur at 8:30 am ET to discuss the results and provide an update on the company's business. Participants can pre-register for the call to receive dial-in numbers and PINs. The audio webcast will also be accessible on the company's website.
Autolus Therapeutics (Nasdaq: AUTL) announced its participation in William Blair’s Biotech Focus Conference 2022 in New York City on July 12. CEO Dr. Christian Itin will join a panel discussion titled ‘Operationalizing Cell Therapies’ from 8:55 to 10:15 am ET. The company aims to advance next-generation programmed T cell therapies for cancer treatment. With proprietary technologies, Autolus develops targeted T cell therapies designed to combat various cancers, focusing on hematological malignancies and solid tumors.
Autolus Therapeutics (Nasdaq: AUTL) announced significant clinical data at the European Hematology Association Congress from June 9-12, 2022. Key highlights include:
- AUTO4: Shows promising activity for T cell lymphoma with favorable safety profiles.
- AUTO1/22: Demonstrates strong remission rates in children with B-ALL, even those unresponsive to existing CAR T therapies.
- Obe-cel: Exhibits sustained efficacy in B-NHL and emerging activity in Primary CNS Lymphoma.
A conference call will take place on June 13, 2022, at 7:30 AM EST to discuss these findings.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced its Annual General Meeting (AGM) to be held on June 28, 2022, in London. The official notice for shareholders details the meeting's agenda, which includes ordinary and special resolutions. The company will announce the results of the voting via a press release following the AGM. Autolus is focused on developing advanced T cell therapies for cancer treatment, utilizing proprietary technologies to create targeted therapies aimed at hematological malignancies and solid tumors.
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in the Jefferies Healthcare Conference in New York City on June 9, 2022. CEO Dr. Christian Itin will engage in a Fireside Chat from 9:00 to 9:30 am ET. The company will also hold one-on-one investor meetings at the event. An audio webcast of the Fireside Chat will be available on Autolus' website, with an archived version accessible for a limited period post-conference. Autolus specializes in programmed T cell therapies aimed at treating various cancers.
FAQ
What is the current stock price of Autolus Therapeutics plc American Depositary Share (AUTL)?
What is the market cap of Autolus Therapeutics plc American Depositary Share (AUTL)?
What does Autolus Therapeutics plc do?
What are the key products in Autolus' pipeline?
Who are Autolus' strategic partners?
What are the financial highlights for Autolus?
What recent milestones has Autolus achieved?
What are the anticipated milestones for obe-cel?
What is the significance of Autolus' therapies?
How does Autolus' financial condition support its research?
Where is Autolus Therapeutics plc listed?
What is the mission of Autolus Therapeutics plc?
